IMMEDIATE ACTION REQUIRED: (1) Billing team must update prior authorization requirements in all billing software systems to REMOVE prior auth requirements for: Rytelo, Ohtuvayre, Sofdra, Zoryve 0.15% cream, Vafseo, Vigafyde, Voranigo, Crexont, Neffy, Lazcluze, Tryvio, Lodoco, Femlyv, Cobenfy, Vyalev, Itovebi, Aurlumyn, Revuforj, Danziten, Imkeldi, Qlosi, and Journavx (30 tablets per 90 days quantity limit). (2) Billing team must update formulary exclusion lists to ADD: Nemluvio, Onyda XR, Ebglyss, Hympavzi, Opipza, Emrosi, Nypozi, and Alhemo as non-covered for MVP Commercial, Marketplace, and Self-Funded plans. (3) Update all formulary verification tools and prior authorization workflows to reflect these changes effective on each member's plan year start date (typically January 1, 2025 or member-specific plan dates). (4) Notify all providers that prior authorization is no longer required for the 15 removed medications to prevent unnecessary claim delays. (5) Providers must verify coverage before prescribing the 5 newly excluded medications to avoid member cost-sharing issues. Failure to update systems will result in either unnecessary prior authorization denials or coverage denials for excluded drugs.